Research Analysts Set Expectations for RARE FY2027 Earnings

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) – Analysts at Wedbush boosted their FY2027 earnings per share (EPS) estimates for shares of Ultragenyx Pharmaceutical in a research report issued on Thursday, January 23rd. Wedbush analyst L. Chico now forecasts that the biopharmaceutical company will post earnings of $1.05 per share for the year, up from their previous estimate of $1.04. Wedbush has a “Neutral” rating and a $48.00 price objective on the stock. The consensus estimate for Ultragenyx Pharmaceutical’s current full-year earnings is ($6.14) per share. Wedbush also issued estimates for Ultragenyx Pharmaceutical’s FY2028 earnings at $1.92 EPS.

Several other equities analysts have also recently issued reports on RARE. HC Wainwright reissued a “buy” rating and issued a $95.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Tuesday, December 24th. Wells Fargo & Company boosted their price objective on Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the company an “overweight” rating in a report on Friday, December 20th. Cantor Fitzgerald reissued an “overweight” rating and issued a $118.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Wednesday. Piper Sandler boosted their price objective on Ultragenyx Pharmaceutical from $135.00 to $140.00 and gave the company an “overweight” rating in a report on Monday, January 13th. Finally, TD Cowen boosted their price objective on Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the company a “buy” rating in a report on Monday, October 21st. One equities research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $92.43.

Ultragenyx Pharmaceutical Stock Performance

Ultragenyx Pharmaceutical stock opened at $44.05 on Friday. The business’s 50-day simple moving average is $44.56 and its two-hundred day simple moving average is $49.57. The company has a market cap of $4.07 billion, a PE ratio of -6.81 and a beta of 0.58. Ultragenyx Pharmaceutical has a fifty-two week low of $37.02 and a fifty-two week high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) earnings per share for the quarter, beating the consensus estimate of ($1.45) by $0.05. The business had revenue of $139.49 million for the quarter, compared to the consensus estimate of $135.28 million. Ultragenyx Pharmaceutical had a negative return on equity of 187.12% and a negative net margin of 106.93%. The company’s quarterly revenue was up 42.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($2.23) EPS.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

Hedge funds have recently made changes to their positions in the company. True Wealth Design LLC acquired a new position in shares of Ultragenyx Pharmaceutical during the third quarter valued at approximately $43,000. Values First Advisors Inc. purchased a new stake in shares of Ultragenyx Pharmaceutical in the third quarter valued at approximately $56,000. Wilmington Savings Fund Society FSB purchased a new stake in shares of Ultragenyx Pharmaceutical in the third quarter valued at approximately $83,000. Nomura Asset Management Co. Ltd. purchased a new stake in shares of Ultragenyx Pharmaceutical in the third quarter valued at approximately $93,000. Finally, R Squared Ltd purchased a new stake in shares of Ultragenyx Pharmaceutical in the fourth quarter valued at approximately $103,000. Institutional investors and hedge funds own 97.67% of the company’s stock.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis sold 11,727 shares of the stock in a transaction that occurred on Monday, December 30th. The stock was sold at an average price of $42.23, for a total transaction of $495,231.21. Following the completion of the transaction, the chief executive officer now owns 2,183,985 shares of the company’s stock, valued at $92,229,686.55. This represents a 0.53 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 5.80% of the company’s stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.